Phase 1 Study of MKC-1 in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to determine the highest dose of MKC-1 that may be administered
daily on a continuous basis for patients with advanced or refractory solid tumors.